Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124602 | 0.90 | BDKRB1 (0.49) | BDKRB1KDM2BKMT2AMEN1 | |
| SCHEMBL5124621 | 0.86 | BDKRB1 (0.45) | BDKRB1MAPTKEAP1 | |
| SCHEMBL5114434 | 0.84 | BDKRB1 (0.45) | BDKRB1KEAP1 | |
| SCHEMBL5114202 | 0.84 | BDKRB1 (0.52) | BDKRB1KDM2BKMT2AMEN1 | |
| SCHEMBL5125279 | 0.84 | BDKRB1 (0.45) | BDKRB1 | |
| SCHEMBL5125270 | 0.84 | BDKRB1 (0.45) | BDKRB1 | |
| SCHEMBL5118650 | 0.84 | BDKRB1 (0.46) | BDKRB1 | |
| SCHEMBL5111735 | 0.84 | BDKRB1 (0.45) | BDKRB1KMT2AMEN1POLB | |
| SCHEMBL5125531 | 0.83 | KMT2A (0.46) | BDKRB1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5124189 | 0.83 | BDKRB1 (0.51) | BDKRB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885MAPT 4123/4885KDM2B 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.